- Home
- BBIO vs RARE Comparison
BBIO vs RARE Comparison
Compare BBIO & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- RARE
- Stock Information
- Founded
- BBIO 2015
- RARE 2010
- Country
- BBIO United States
- RARE United States
- Employees
- BBIO N/A
- RARE N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- BBIO Health Care
- RARE Health Care
- Exchange
- BBIO Nasdaq
- RARE Nasdaq
- Market Cap
- BBIO 4.9B
- RARE 5.2B
- IPO Year
- BBIO 2019
- RARE 2014
- Fundamental
- Price
- BBIO $23.24
- RARE $46.02
- Analyst Decision
- BBIO Strong Buy
- RARE Strong Buy
- Analyst Count
- BBIO 13
- RARE 14
- Target Price
- BBIO $46.92
- RARE $86.79
- AVG Volume (30 Days)
- BBIO 1.7M
- RARE 974.4K
- Earning Date
- BBIO 11-12-2024
- RARE 11-05-2024
- Dividend Yield
- BBIO N/A
- RARE N/A
- EPS Growth
- BBIO N/A
- RARE N/A
- EPS
- BBIO N/A
- RARE N/A
- Revenue
- BBIO $217,765,000.00
- RARE $522,745,000.00
- Revenue This Year
- BBIO $3,690.39
- RARE $27.29
- Revenue Next Year
- BBIO N/A
- RARE $18.30
- P/E Ratio
- BBIO N/A
- RARE N/A
- Revenue Growth
- BBIO 2209.77
- RARE 27.44
- 52 Week Low
- BBIO $21.62
- RARE $37.02
- 52 Week High
- BBIO $44.32
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- BBIO 41.84
- RARE 34.61
- Support Level
- BBIO $21.72
- RARE $43.04
- Resistance Level
- BBIO $27.57
- RARE $53.04
- Average True Range (ATR)
- BBIO 1.42
- RARE 2.14
- MACD
- BBIO -0.23
- RARE -0.35
- Stochastic Oscillator
- BBIO 25.98
- RARE 28.57
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.